p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer

European Journal of Surgical Oncology

Volumn 22, Issue 2, 1996, Pages 182-185

  Brett, Martin C ^a   Pickard, Mark ^a   Green, Bryan ^a   Howel Evans, Amanda ^a   Smith, David ^b   Kinsella, Anne ^a   Poston, Graeme ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

Author keywords

5 fluorouracil chemotherapy; Advanced colorectal cancer; p53 protein overexpression

Indexed keywords

FLUOROURACIL; FOLINIC ACID; ONDANSETRON; PROTEIN P53; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER GRADING; CANCER SURVIVAL; CELL CYCLE; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DNA DAMAGE; FEMALE; GENDER; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

EID: 0029958791     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0748-7983(96)90827-6     Document Type: Article

References (27)

1. Petrelli N, Herrera L, Rustum Y, et al. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987; 5: 1559-65.
2. Petrelli N, Douglass HO, Herrera L, et al. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. J Clin Oncol 1989; 7: 1419-26.
3. Erlichman C, Fine S, Wong A, Elkahim T. A randomized trial of fluorouracil with folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988; 6: 469-75.
4. Poon MA, O'Connell MJ, Moertel CG, et al. Biochemical modulation of fluorouracil: evidence of significant improvement in survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989; 7: 1407-18.
5. Valone FH, Friedman MA, Wittlinger PS, et al. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil and leucovorin: a randomized trial of the Northern California Oncology Group. J Clin Oncol 1989; 7: 1427-36.
6. Doroshow JH, Multhauf P, Leong L, et al. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990; 8: 491-501.
7. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid-Atlantic Oncology Program study. J Clin Oncol 1989; 7: 425-32.
8. Baker SJ, Fearon ER, Nigro JM, et al. Chromosome 17 deletion and p53 mutations in colorectal carcinomas. Science 1989; 244: 217-21.
9. Lane DP. P53, guardian of the genome. Nature 1992; 358: 15-6.
10. Kastan MB, Onyerwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the Cellular Response to DNA Damage. Cancer Res 1991; 51: 6304-11.
11. Levine AJ, Perry ME, Chang A, et al. The 1993 Walter Hubert Lecture: the role of the p53 tumour-suppressor gene in tumorigenesis. Br J Cancer 1994; 69: 409-16.
12. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 1991; 353: 345-7.
13. Nelson WG, Kastan MB. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994; 14: 1815-23.
14. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993; 74: 957-67.
15. Harris CC, Hollstein M. Clinical implications of the p53 tumour suppressor gene. N Engl J Med 1993; 329: 1318-27.
16. Santi DV, Danenberg D. Folates in pyrimidine nucleotide biosinthesis. In Blakely R, Benkovic R (eds) Folates and Pterins. New York: Wiley, 1984: 345-98.
17. Curtin NJ, Harris AL, Aherne GW. Mechanisms of cell death following thymidylate synthesis inhibition, 2-deoxyuridine-5′-triphosphate accumulation, DNA damage and growth inhibition following exposure to CB371 and dipyridamole. Cancer Res 1991; 51: 2346-52.
18. Grem JL, Fischer PH. Enhancement of 5-fluorouracil's anticancer activity by dipyridamole. Pharmacol Ther 1989; 40: 349-71.
19. Bleyer WA. New vistas for leucovorin in cancer chemotherapy. Cancer 1989; 63: 995-1007.
20. Kemeny N, Braun DW. Prognostic factors in advanced colorectal cancer. Importance of lactic dehydrogenase level, performance status, white blood cell count. Am J Med 1983; 74: 786.
21. Vogelstein B. Kinzler KW. P53 function and dysfunction. Cell 1992; 70: 523-6.
22. Starzynska T, Bromley M, Ghosh A, Stern PL. Prognostic significance of p53 overexpression in gastric and colorectal carcinoma. Br J Cancer 1992; 66: 558-62.
23. Hamilton SR. Molecular genetics of colorectal carcinoma. Cancer 1992; 70 (Suppl 5): 1216-21.
24. Sun XF, Carstensen JM, Stal O, et al. Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma. Virchows Arch A Pathol Anat Histopathol 1993; 423: 443-8.
25. Hamelin R, Laurent-Puig P, Olschwang S, et al. Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 1994: 106: 42-8.
26. Scott N, Sagar P, Stewart J, Blair GE, Dixon MF, Quirke P. p53 in colorectal cancer: clinicopathological correlation and prognostic significance. Br J Cancer 1991; 63: 317-9.
27. Pickard M, Dive C, Kinsella AR. Differences in resistance to 5-FU as a function of cell cycle delay not apoptosis. Br J Cancer 1995; 72: 1389-96.